Showing results (41-50 of 52) with videos related to
Sort By:
Pageof 6
Cancer|October 30, 2015
Clinicopathologic features of breast cancers that develop in women with previous benign breast diseaseDaniel W Visscher, Marlene H Frost, Lynn C Hartmann, et al.BMC Medical Genomics|December 22, 2010
Expression profiling of formalin-fixed paraffin-embedded primary breast tumors using cancer-specific and whole genome gene panels on the DASL® platformMonica M Reinholz, Jeanette E Eckel-Passow, S Keith Anderson, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 23, 2013
Impact of c-MYC protein expression on outcome of patients with early-stage HER2+ breast cancer treated with adjuvant trastuzumab NCCTG (alliance) N9831Amylou C Dueck, Monica M Reinholz, Xochiquetzal J Geiger, et al.BMC Cancer|October 8, 2014
ERβ1: characterization, prognosis, and evaluation of treatment strategies in ERα-positive and -negative breast cancerJordan M Reese, Vera J Suman, Malayannan Subramaniam, et al.Science Translational Medicine|August 9, 2019
Personalized circulating tumor DNA analysis to detect residual disease after neoadjuvant therapy in breast cancerBradon R McDonald, Tania Contente-Cuomo, Stephen-John Sammut, et al.Plos One|March 28, 2015
Folate receptor-α (FOLR1) expression and function in triple negative tumorsBrian M Necela, Jennifer A Crozier, Cathy A Andorfer, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 22, 2015
Genomic analysis reveals that immune function genes are strongly linked to clinical outcome in the North Central Cancer Treatment Group n9831 Adjuvant Trastuzumab TrialEdith A Perez, E Aubrey Thompson, Karla V Ballman, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 20, 2011
C-MYC alterations and association with patient outcome in early-stage HER2-positive breast cancer from the north central cancer treatment group N9831 adjuvant trastuzumab trialEdith A Perez, Robert B Jenkins, Amylou C Dueck, et al.European Journal of Cancer (Oxford, England : 1990)|March 25, 2021
Updated results from the international phase III ALTTO trial (BIG 2-06/Alliance N063D)Alvaro Moreno-Aspitia, Eileen M Holmes, Christian Jackisch, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 25, 2015
Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization TrialMartine Piccart-Gebhart, Eileen Holmes, José Baselga, et al.Pageof 6